Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027

뉴스 본문을 불러오고 있어요.

Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027 | 웨이프 WAPE

Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027

기사 요약

관련 종목

댓글 —